SEARCH

SEARCH BY CITATION

References

  • 1
    Silverberg E, Lubera JA. Cancer statistics. CA 1989; 39: 320.
  • 2
    Ozols RF, Young RC. Chemotherapy of ovarian cancer. Semin Oncol 1991; 18: 22232.
  • 3
    Ozols RF, Young RC. Ovarian cancer. In: Haskell CM, editor. Current problems in cancer. vol. II. Chicago: Year Book Medical Publishers, 1987: 57122.
  • 4
    Piver MS, Rose PG. Chemotherapy of epithelial ovarian cancer. In: Deppe G, editor. Chemotherapy of gynecologic cancer. 2nd ed. New York: Alan R. Liss, 1990: 175216.
  • 5
    Perez RP, Hamilton TC, Ozols RF. Resistance to alkylating agents and cisplatin: insights from ovarian carcinoma model systems. Pharmacol Ther 1990; 48: 1927.
  • 6
    Hamilton TC. Common epithelial tumors of the ovary: Part I. biology. Curr Probl Cancer 1992; 16: 457.
  • 7
    Hamilton TC, Young RC, Ozols RF. Experimental model systems of ovarian cancer: applications to the design and evaluation of new treatment approaches. Semin Oncol 1984; 11: 28598.
  • 8
    Hamilton TC, Young RC, Louie KG, Behrens BC, McKoy WM, Grotzinger KR, et al. Characterization of a xenograft model of human ovarian cancer which produces ascites and intraabdominal carcinomatosis. Cancer Res 1984; 44: 528690.
  • 9
    Ozols RF, Louie KG, Plowman J, Behrens BC, Fine RL, Dykes D, et al. Enhanced melphalan cytotoxicity in human ovarian cancer in vitro and in tumor-bearing nude mice by buthionine sulfoximine depletion of glutathione. Biochem Pharmacol 1987; 36: 14753
  • 10
    Andrews PA, Jones JA, Varki NM, Howell SB. Rapid emergence of acquired cis-diamminedichloroplatinum (II) resistance in an in vivo model of ovarian carcinoma. Cancer Commun 1990; 2: 93100.
  • 11
    Hayes JD, Wolf CR. Molecular mechanisms of drug resistance. Biochem J 1990; 272: 28195.
  • 12
    Andrews PA, Howell SB. Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance. Cancer Cells 1990; 2: 3543.
  • 13
    Hospers GAP, Mulder NH, deVries EGE. Mechanisms of cellular resistance to cisplatin. Med Oncol Tumor Pharmacother 1988; 5: 14551.
  • 14
    de Graeff A, Slebos RJC, Rodenhuis S. Resistance to cisplatin and analogues: mechanisms and potential clinical implications. Cancer Chemother Pharmacol 1988; 22: 32532.
  • 15
    Fojo A, Hamilton TC, Young RC, Ozols RF. Multidrug resistance in ovarian cancer. Cancer 1987; 60: 207580.
  • 16
    Ozols RF, Hamilton TC, Masuda H, Young RC. Manipulation of cellular thiols to influence drug resistance. In: Woolley PV III, Tew KD, editors. Mechanisms of drug resistance in neoplastic cells San Diego: Academic Press, 1989: 289306.
  • 17
    Andrews PA, Mann SC, Velury S, Howell SB. Cisplatin uptake mediated cisplatin-resistance in human ovarian carcinoma cells. In: Nicolini M, editor. Platinum and other metal coordination compounds in cancer chemotherapy. Boston: Martinus Nijhoff, 1988: 24854.
  • 18
    Mann SC, Andrews PA, Howell SB. Short-term cis-diammine-dicholoroplatinum (II) accumulation in sensitive and resistant human ovarian carcinoma cells. Cancer Chemother Pharmacol 1990; 25: 23640.
  • 19
    Andrews PA, Mann SC, Huynh HH, Albright KD. Role of the Na+, K+-adenosine triphosphatase in the accumulation of cis-diamminedichloroplatinum (II) in human ovarian carcinoma cells. Cancer Res 1991; 51: 367781.
  • 20
    Mann SC, Andrews PA, Howell SB. Modulation of cis-diamminedichloroplatinum (II) accumulation and sensitivity by forskolin and 3-isobutyl-1-methylxanthine in sensitive and resistant human ovarian carcinoma cells. Int J Cancer 1991; 48: 86672.
  • 21
    Shionoya S, Lu Y, Scanlon KJ. Properties of amino acid transport systems in K562 cells sensitive and resistant to cis-diamminedichloroplatinum (II). Cancer Res 1986; 46: 34458.
  • 22
    Andrews PA, Velury S, Mann SC, Howell SB. cis-diamminedichloroplatinum (II) accumulation in sensitive and resistant human ovarian carcinoma cells. Cancer Res 1988; 48: 6873.
  • 23
    Kuppen PJK, Schuitemaker H, van't Veer LJ, de Bruijn EA, van-Oosteron AT, Schrier PI. cis-Diamminedichloroplatinum (II)-resistant sublines derived from two human ovarian tumor cell lines. Cancer Res 1988; 48: 33559.
  • 24
    Kawai K, Kamatani N, Georges E, Ling V. Identification of a membrane glycoprotein overexpressed in murine lymphoma sublines resistant to cis-diamminedichloroplatinum (II). J Biol Chem 1990; 265: 1313742.
  • 25
    Behrens BC, Hamilton TC, Masuda H, Grotzinger KR, Whang-Peng J, Louie KG, et al. Characterization of a cis-diamminedichloroplatinum (II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues. Cancer Res 1987; 47: 4148.
  • 26
    Eastman A. Cross-linking of glutathione to DNA by cancer che-motherapeutic platinum coordination complexes. Chem Biol Interact 1987; 61: 2418.
  • 27
    Mistry P, Kelland LR, Abel G, Sidhar S, Harrop KR. The relationships between glutathione, glutathione-S-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell lines. Br J Cancer 1991; 64: 21520.
  • 28
    Hamilton TC, Winker MA, Louie KG, Batist G, Behrens BC, Tsuruo T, et al. Augmentation of adriamycin, melphalan and cisplatin cytotoxicity in drug-resistant and -sensitive human ovarian cancer cell lines by buthionine sulfoximine mediated glutathione depletion. Biochem Pharmacol 1985; 34: 25836.
  • 29
    Louie KG, Behrens BC, Kinsella TJ, Hamilton TC, Grotzinger KR, McKoy WM, et al. Radiation survival parameters of antineoplastic drug-sensitive and -resistant human ovarian cancer cell lines and their modification by buthionine sulfoximine. Cancer Res 1985; 45: 21105.
  • 30
    Lewis AD, Hayes JD, Wolf CR. Glutathione and glutathione-dependent enzymes in ovarian adenocarcinoma cell lines derived from a patient before and after the onset of drug resistance: intrinsic differences and cell cycle effects. Carcinogenesis 1988; 9: 12837.
  • 33
    Barranco SC, Townsend CM, Weintraub B, Beasley EG, MacLean KK, Schaeffer J, et al. Changes in glutathione content and resistance to anticancer agents in human stomach cancer cells induced by treatments with melphalan in vitro. Cancer Res 1990; 50: 36148.
  • 34
    Suzukake K, Ptero B, Vistica D. Reduction in glutathione content of L-PAM resistant L1210 cells confers drug sensitivity. Biochem Pharmacol 1982; 31: 1214.
  • 35
    Meister A. Novel drugs that affect glutathione metabolism. In: Woolley PV III, Tew KD, editors. Mechanisms of drug resistance in neoplastic cells. San Diego: Academic Press, 1988: 99126.
  • 36
    Green JA, Vistica DT, Young RC, Hamilton TC, Rogan AM, Ozols RF. Melphalan resistance in human ovarian cancer: characterization of drug resistant cell lines and potentiation of melphalan cytotoxicity by glutathione depletion. Cancer Res 1984; 44: 542731.
  • 37
    O'Dwyer PJ, Hamilton TC, Young RC, Carp N, Tew KD, Padavic K, et al. Depletion of glutathione in normal and malignant human cells in vivo by buthionine sulfoximine: clinical and biochemical results. J Natl Cancer Inst 1992; 84: 2647.
  • 38
    Tew KD, Clapper ML. Glutathione S-transferases and anticancer drug resistance. In: Woolley PV III, Tew KD, editors. Mechanisms of drug resistance in neoplastic cells. San Diego: Academic Press, 1988: 14159.
  • 39
    Hamer D. Metallothionein. Annu Rev Biochem 1986; 55: 91351.
  • 40
    Kelley SL, Basu A, Teicher BA, Hacker MP, Hamer DH, Lazo JS. Overexpression of metallothionein confers resistance to anticancer drugs. Science 1988; 241: 18135.
  • 41
    Kasahara K, Fujiwara Y, Nishio K, Ohmori T, Sugimoto Y, Komiya K, et al. Metallothionein content correlates with the sensitivity of human small cell lung cancer cell lines to cisplatin. Cancer Res 1991; 51: 323742.
  • 42
    Lohrer H, Robson T. Overexpression of metallothionein in CHO cells and its effect on cell killing by ionizing radiation and alkylating agents. Carcinogenesis 1989; 10: 227984.
  • 43
    Schilder RJ, Hall L, Monks A, Handel LM, Fornace AJ Jr., Ozols RF, et al. Metallothionein gene expression and resistance to cisplatin in human ovarian cancer. Int J Cancer 1990; 45: 41622.
  • 44
    Andrews PA, Murphy MP, Howell SB. Metallothionein-mediated cisplatin resistance in human ovarian cancer cells. Cancer Chemother Pharmacol 1987; 19: 14954.
  • 45
    Murphy D, McGown AT, Crowther D, Mander A, Fox BW. Metallothionein levels in ovarian tumours before and after chemotherapy. Br J Cancer 1991; 63: 7114.
  • 46
    Eastman A. The formation, isolation and characterization of DNA adducts produced by anticancer platinum complexes. Pharmacol Ther 1987; 34: 15566.
  • 47
    Reedijk J. The mechanism of action of platinum anti-tumor drugs. Pure Appl Chem 1987; 59: 18192.
  • 48
    Lippard SJ. Chemistry and molecular biology of platinum anticancer drugs. Pure Appl Chem 1987; 59: 73142.
  • 49
    Fichtinger-Schepmann AMJ, van der Veer JL, den Hartog JHJ, Lohman PHM, Reedijk J. Adducts of the antitumor drug cis-diamminedichloroplatinum (II) with DNA: formation, identification and quantitation. Biochemistry 1985; 24: 70713.
  • 50
    Plooy ACM, Fichtinger-Schepman AMJ, Schulte HH, van Dijk M, Lohman PHM. The quantitative detection of various Pt-DNA adducts in Chinese hamster ovary cells treated with cisplatin application of immunochemical techniques. Carcinogenesis 1985; 6: 5616.
  • 51
    Micetich K, Zwelling LA, Kohn KW. Quenching of DNA: platinum (II) monoadducts as a possible mechanism of resistance to cis-diamminedichloroplatinum (II) in L1210 cells. Cancer Res 1983; 43: 360913.
  • 52
    Ali-Osman F. Quenching of DNA cross-link precursors of chloroethylnitrosureas and attenuation of DNA interstrand cross-linking by glutathione. Cancer Res 1989; 49: 525861.
  • 53
    Lai G-M, Ozols RF, Smyth JF, Young RC, Hamilton TC. Enhanced DNA repair and resistance to cisplatin in human ovarian cancer. Biochem Pharmacol 1988; 37: 45974600.
  • 54
    Masuda H, Ozols RF, Lai G-M, Fojo A, Rothenberg M, Hamilton TC. Increased DNA repair as a mechanism of acquired resistance to cis-diamminedichloroplatinum (II) in human ovarian cancer cell lines. Cancer Res 1988; 48: 57136.
  • 55
    Masuda H, Tanaka T, Matsuda H, Kusaka I. Increased removal of DNA-bound platinum in a human ovarian cancer cell line resistant to cis-diamminedichloroplatinum (II). Cancer Res 1990; 50: 18636.
  • 56
    Parker RJ, Eastman A, Bostick-Burton F, Reed E. Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation. J Clin Invest 1991; 87: 7727.
  • 57
    Eastman A, Schulte N. Enhanced DNA repair as a mechanism of resistance to cis-diamminedichloroplatinum (II). Biochemistry 1988; 27: 47304.
  • 58
    Batist G, Torres-Garcia S, Demuys J-M, Greene D, Lehnert S, Rochon M, et al. Enhanced DNA cross-link removal: the apparent mechanism of resistance in a clinically relevant melphalan-resistant human breast cancer cell line. Mol Pharmacol 1989; 36: 22430.
  • 59
    Bohr VA. Differential DNA repair within the genome. Cancer Rev 1987; 7: 2855.
  • 60
    Hanawalt PC. Heterogeneity of DNA repair at the gene level. Mutat Res 1991; 247: 20311.
  • 61
    Katz EJ, Andrews PA, Howell SB. The effect of DNA polymerase inhibitors on the cytotoxicity of cisplatin in human ovarian carcinoma cells. Cancer Commun 1990; 2: 15964.
  • 62
    Dempke WCM, Shellard SA, Fichtinger-Schepman AMJ, Hill BT. Lack of significant modulation of the formation and removal of platinum DNA adducts by aphidicolin glycinate in two logarithmically-growing ovarian tumor cell lines in vitro. Carcinogenesis 1991; 12: 5258.
  • 63
    Scanlon KJ, Kashani-Sabet M, Sowers LC. Overexpression of DNA replication and repair enzymes in cisplatin-resistant human colon carcinoma HCT8 cells and circumvention by azidothymidine. Cancer Commun 1989; 1: 26975.
  • 64
    Frankfurt OS. Inhibition of DNA repair and the enhancement of cytotoxicity of alkylating agents. Int J Cancer 1991; 48: 91623.
  • 65
    Eder JP, Teicher BA, Holden SA, Cathcart KNS, Schnipper LE. Novobiocin enhances alkylating agent cytotoxicity and DNA interstrand crosslinks in a murine model. J Clin Invest 1987; 79: 15248.
  • 66
    Hoeijmakers JHJ, Bootsma D. Molecular genetics of eukaryotic DNA excision repair. Cancer Cells 1990; 2: 31120.
  • 67
    Thompson LH. Properties and applications of human DNA repair genes. Mutat Res 1991; 247: 2139.
  • 68
    Andrews PA, Jones JA. Characterization of binding proteins from ovarian carcinoma and kidney tubule cells that are specific for cisplatin modified DNA. Cancer Commun 1991; 3: 110.
  • 69
    Chao CC-K. Potential negative regulation of damage-recognition proteins in cisplatin-resistant HeLa cells in response to DNA damage. Mutat Res 1991; 264: 5966.
  • 70
    Chu G, Chang E. Cisplatin-resistant cells express increased levels of a factor that recognizes damaged DNA. Proc Natl Acad Sci USA 1990; 87: 33247.